Literature DB >> 15383654

Role of caveolae and caveolins in health and disease.

Alex W Cohen1, Robert Hnasko, William Schubert, Michael P Lisanti.   

Abstract

Although they were discovered more than 50 years ago, caveolae have remained enigmatic plasmalemmal organelles. With their characteristic "flasklike" shape and virtually ubiquitous tissue distribution, these interesting structures have been implicated in a wide range of cellular functions. Similar to clathrin-coated pits, caveolae function as macromolecular vesicular transporters, while their unique lipid composition classifies them as plasma membrane lipid rafts, structures enriched in a variety of signaling molecules. The caveolin proteins (caveolin-1, -2, and -3) serve as the structural components of caveolae, while also functioning as scaffolding proteins, capable of recruiting numerous signaling molecules to caveolae, as well as regulating their activity. That so many signaling molecules and signaling cascades are regulated by an interaction with the caveolins provides a paradigm by which numerous disease processes may be affected by ablation or mutation of these proteins. Indeed, studies in caveolin-deficient mice have implicated these structures in a host of human diseases, including diabetes, cancer, cardiovascular disease, atherosclerosis, pulmonary fibrosis, and a variety of degenerative muscular dystrophies. In this review, we provide an in depth summary regarding the mechanisms by which caveolae and caveolins participate in human disease processes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15383654     DOI: 10.1152/physrev.00046.2003

Source DB:  PubMed          Journal:  Physiol Rev        ISSN: 0031-9333            Impact factor:   37.312


  307 in total

1.  Elevated inflammatory response in caveolin-1-deficient mice with Pseudomonas aeruginosa infection is mediated by STAT3 protein and nuclear factor kappaB (NF-kappaB).

Authors:  Kefei Yuan; Canhua Huang; John Fox; Madeleine Gaid; Andrew Weaver; Guoping Li; Brij B Singh; Hongwei Gao; Min Wu
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

2.  Trypanosoma cruzi infection results in the reduced expression of caveolin-3 in the heart.

Authors:  Daniel Adesse; Michael P Lisanti; David C Spray; Fabiana S Machado; Maria de Nazareth Meirelles; Herbert B Tanowitz; Luciana Ribeiro Garzoni
Journal:  Cell Cycle       Date:  2010-04-15       Impact factor: 4.534

3.  Solubilization of a membrane protein by combinatorial supercharging.

Authors:  Agnes Hajduczki; Sudipta Majumdar; Marie Fricke; Isola A M Brown; Gregory A Weiss
Journal:  ACS Chem Biol       Date:  2011-01-14       Impact factor: 5.100

4.  Diabetes-related alterations in the enteric nervous system and its microenvironment.

Authors:  Mária Bagyánszki; Nikolett Bódi
Journal:  World J Diabetes       Date:  2012-05-15

5.  Loss of caveolin-1 causes blood-retinal barrier breakdown, venous enlargement, and mural cell alteration.

Authors:  Xiaowu Gu; Steven J Fliesler; You-Yang Zhao; William B Stallcup; Alex W Cohen; Michael H Elliott
Journal:  Am J Pathol       Date:  2013-12-08       Impact factor: 4.307

Review 6.  Biochemical markers of aging for longitudinal studies in humans.

Authors:  Peter M Engelfriet; Eugène H J M Jansen; H Susan J Picavet; Martijn E T Dollé
Journal:  Epidemiol Rev       Date:  2013-02-04       Impact factor: 6.222

7.  Caveolin-3 associates with and affects the function of hyperpolarization-activated cyclic nucleotide-gated channel 4.

Authors:  Bin Ye; Ravi C Balijepalli; Jason D Foell; Stacie Kroboth; Qi Ye; Yu-Hong Luo; Nian-Qing Shi
Journal:  Biochemistry       Date:  2008-11-25       Impact factor: 3.162

8.  RNA interference as a potential therapeutic treatment for inflammation associated lung injury.

Authors:  Joanne Lomas-Neira; Chun-Shiang Chung; Alfred Ayala
Journal:  Int J Clin Exp Med       Date:  2008-02-25

9.  Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: Caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells.

Authors:  Terence M Williams; Federica Sotgia; Hyangkyu Lee; Ghada Hassan; Dolores Di Vizio; Gloria Bonuccelli; Franco Capozza; Isabelle Mercier; Hallgeir Rui; Richard G Pestell; Michael P Lisanti
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

10.  Agonist treatment did not affect association of mu opioid receptors with lipid rafts and cholesterol reduction had opposite effects on the receptor-mediated signaling in rat brain and CHO cells.

Authors:  Peng Huang; Wei Xu; Su-In Yoon; Chongguang Chen; Parkson Lee-Gau Chong; Ellen M Unterwald; Lee-Yuan Liu-Chen
Journal:  Brain Res       Date:  2007-10-12       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.